Adam Crystal
President, R&D · 5 filings · Latest: Jun 1, 2026
Tango Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
TNGX | Adam Crystal | President, R&D | Jun 1, 2026 | Sale | $22.87 | 27,000 | $617.6K | 115,743 | |
TNGX | Adam Crystal | President, R&D | Jun 1, 2026 | Option Exercise | $5.20 | 27,000 | $140.4K | 142,743 | |
TNGX | Adam Crystal | President, R&D | May 1, 2026 | Sale | $21.23 | 27,000 | $573.1K | 115,743 | |
TNGX | Adam Crystal | President, R&D | May 1, 2026 | Option Exercise | $5.20 | 27,000 | $140.4K | 142,743 | |
TNGX | Adam Crystal | President, R&D | Apr 15, 2026 | Sale | $25.00 | 38,460 | $961.5K | 112,622 | |
TNGX | Adam Crystal | President, R&D | Apr 15, 2026 | Option Exercise | $5.20 | 38,460 | $200.0K | 151,082 | |
TNGX | Adam Crystal | President, R&D | Apr 1, 2026 | Sale | $21.20 | 27,000 | $572.5K | 112,622 | |
TNGX | Adam Crystal | President, R&D | Apr 1, 2026 | Option Exercise | $5.20 | 27,000 | $140.4K | 139,622 | |
TNGX | Adam Crystal | President, R&D | Mar 25, 2026 | Sale | $20.11 | 12,000 | $241.3K | 112,622 | |
TNGX | Adam Crystal | President, R&D | Mar 25, 2026 | Option Exercise | $5.20 | 12,000 | $62.4K | 124,622 |